We wanted to investigate whether urine albumin/creatinine ratio (UACR) and left ventricular (LV) mass, both being associated with diabetes and increased blood pressure, predicted cardiovascular events in patients with hypertension independently. After 2 weeks of placebo treatment, clinical, laboratory and echocardiographic variables were assessed in 960 hypertensive patients from the LIFE Echo substudy with electrocardiographic LV hypertrophy. Morning urine albumin and creatinine were measured to calculate UACR. The patients were followed for 6074 months and the composite end point (CEP) of cardiovascular (CV) death, nonfatal stroke or nonfatal myocardial infarction was recorded. The incidence of CEP increased with increasing LV mass (below the lower quartile of 194 g to above the upper quartile of 263 g) in patients with UACR below (6.7, 5.0, 9.1%) and above the median value of 1.406 mg/ mmol (9.7, 17.0, 19
Introduction
High urine albumin-creatinine ratio (UACR) as well as left ventricular (LV) mass has been associated with increased cardiovascular (CV) risk in population studies. 1, 2 We have recently extended these findings to patients with hypertension and electrocardiographic LV hypertrophy. 3 Albuminuria is associated with atherosclerotic risk factors like ageing, diabetes and high blood pressure 4, 5 and is thought to reflect microvascular damage not only in the glomeruli but also in the systemic vasculature 6 with increasing risk of lipid insudation and development of atherosclerosis. 7 Increased LV mass is associated with the same CV risk factors and is associated with vascular hypertrophy. 8 Although they are related to the same CV risk factors, increased UACR may reflect subclinical disease in the small arteries and capillaries, whereas LV mass reflects subclinical disease in the heart and probably in the large arteries. Therefore, we wanted to investigate whether high UACR supplemented high LV mass in predicting the composite end point (CEP) of CV death, nonfatal stroke or nonfatal myocardial infarction in patients with hypertension LV hypertrophy.
11% of the parent trial population. As described elsewhere, 9 patients aged 55-80 years with mean seated blood pressures in the range 160-200 mmHg systolic and/or 95-115 mmHg diastolic after 1 and 2 weeks on placebo treatment. Patients had electrocardiographic LV hypertrophy by either the Cornell voltage-duration product (R aVL þ S V3 þ 6 mV in women 42440 ms Â mV) or Sokolow-Lyon voltage criteria (S V1 þ R V5/6 438 mV). Patients were recruited into the LIFE echocardiography substudy at sites in Denmark, Finland, Iceland, Norway, Sweden, the United Kingdom and the United States. CV disease was defined as coronary artery disease (history of either angina or myocardial infarction), peripheral vascular disease (claudication or peripheral arterial angioplasty) or cerebrovascular disease (stroke or transient ischaemic attack). The patients were randomized to atenolol-or losartan-based antihypertensive regimens for 4450 patient-years of followup. The predefined end point of the LIFE study, a composite CV end point consisting of CV death, fatal and nonfatal myocardial infarction, and fatal and nonfatal stroke, was registered and adjudicated by an independent end point committee.
Echocardiographic methods
Studies were performed using echocardiographs with M-mode, two-dimensional and pulsed, continuous and colour-flow Doppler capabilities, as previously described. 10, 11 Studies were sent to the Cornell Medical Center Echocardiography Reading Center for blinded interpretation by experienced technician and physician readers. LV internal dimension and wall thickness were measured at end-diastole and end-systole following American Society of Echocardiography (ASE) recommendations 12 on up to three cardiac cycles. When optimal orientation of the M-mode cursor could not be obtained, correctly oriented linear dimension measurements were made using two-dimensional imaging by the leading-edge ASE convention. 13 
Calculation of derived variables
End-diastolic LV dimensions were used to calculate LV mass by a formula shown to yield values closely related to necropsy LV weight (r ¼ 0.90, Po0.001) and good reproducibility (RHO ¼ 0.93) between echocardiograms in hypertensive patients with LV hypertrophy.
14 LV mass was considered as an unadjusted variable and also after traditional normalization for body surface area. 10, 11 Standard methods were used to calculate endocardial fractional shortening and ejection fraction. 15 Stroke volume was calculated by the invasively validated aortic annular-leading edge method as (aortic annular cross-sectional area) Â (Doppler time velocity integral of aortic annular flow) 16 and used to calculated cardiac output and total peripheral resistance. The pulse pressure/stroke volume ratio was used as an indirect measure of systemic arterial stiffness. 17 The primary approach used to assess myocardial contractile performance was examination of LV midwall fractional shortening (MWS) in relation to circumferential end-systolic stress (ESS) measured at LV minor axis. 18 The formulae used to calculate MWS and midwall circumferential ESS have been previously described. 15, 18 To evaluate LV performance taking ESS into account, observed shortening was expressed as a percentage of the value predicted from circumferential ESS using equations derived from normal subjects. 18 For convenience, this variable is termed stress-corrected MWS. 19 A partition value of o89.2% for stress-corrected MWS was defined as subnormal, based on the 5th percentile in a previously described reference population of 280 normotensive, nondiabetic, normal weight men and women aged 18-88 years. 20 
Urine albumin excretion
Urine albumin concentration was determined by standard methods 21, 22 by using a turbidimetric method (Hitachi 717 Analyzer, Boehringer Mannheim) 23 ,24 on a single urine specimen taken on the morning of electrocardiography. Both serum and urine creatinine were analysed using the Jaffé reaction without deproteinizing and then quantified by a photometric method (Hitachi 717 Analyzer, Boehringer Mannheim). The urine-albumin concentration, expressed as a ratio to the urinary creatinine concentration, was used as a measure of glomerular vascular permeability to allow for urine dilution. We defined microalbuminuria as UACR X3.5 mg/mmol and macroalbuminuria as UACR X 35.0 mg/mmol. 25 
Statistical analyses
Data management and analysis were performed using the SPSS 10.1 (SPSS, Chicago, IL, USA) software. Data are presented as mean7s.d. for continuous variables and proportions for categorical variables. Unpaired Student's t-test was used to determine differences in continuous variables between groups. Pearson's w 2 -test was used to compare differences in categorical variables between groups. When performing stepwise, backward multiple linear regression analyses calculating the standardized regression quotient for each parameter (r) all basic characteristics (ie age, gender, weight, height, systolic pressure, LV mass, glucose and cholesterol levels) entered the model. Hazard ratios (HRs) and their 95% confidence intervals (in brackets) for CV events were assessed using Cox regression analysis adjusting for potential confounders (ie age, gender, body mass index, systolic pressure, glucose and cholesterol levels, prior CV disease and treatment allocation). Nonsignificant factors were excluded stepwise. Two-tailed Po0.05 indicated statistical significance.
Results
At baseline, LV mass was obtained in 939 of the 960 patients and the patients were divided into three groups according to LV mass below, between or above the lowest (194 g) and highest (263 g) quartiles (Table 1 
CV end points
With increasing LV mass, the incidence of CEP (7.6% (18/236), 10.4% (49/469) and 16.2% (38/234), P ¼ 0.01) as well as CV death (0.8% (2/236), 3.6% (Figure 2) .
The incidence of CEP increased throughout the LV mass groups both in patients with UACR below the median value of 1.406 mg/mmol (6.7% (8/119), 5.0% (11/222), 9.1% (7/77)) and above the median value (9.7% (9/93 In Cox regression analyses, CEP was predicted by UACR after adjustment for Framingham risk score and history of peripheral vascular disease and cerebrovascular disease (Table 3) . LV mass did not enter the model (HR ¼ 1.001 (0.997-1.004)/g, NS). CV death was predicted by UACR independently of LV mass even after adjustment for Framingham risk score, current smoking, history of diabetes and cerebrovascular disease (Table 3) . Stroke was predicted by logUACR (HR ¼ 1.63 (1.14-2.33) per 10-fold increase in UACR, Po0.01) after adjustment for Framingham risk score (HR ¼ 1.04 (1.01-1.07), Po0.01) and history of cerebrovascular disease (HR ¼ 2.25 (1.06-4.79), Po0.05). 
Discussion
UACR and LV mass predicted CEP as well as CV death independently of each other. However, when including other traditional CV risk factors in Cox regression analyses, LV mass did only add significantly to UACR in prediction of CV death. The fact that UACR and LV mass supplemented each other in prediction of CV end points, supports the idea that albuminuria and LV hypertrophy, although both reflecting subclinical hypertensive target organ damage, may be markers of damage in different parts of the CV system. Albuminuria may not only reflect glomerular damage but also systemic damage of the small arteries and capillaries, 26, 27 whereas high LV mass reflects damage of the heart and probably in the large arteries. [28] [29] [30] Our results support previous findings by Wachtell et al 3 using electrocardiographic assessment of LV mass.
Both UACR and LV mass predicted CV death in patients with history of CV disease indicating that they are not simply markers of preclinical disease and may by themselves increase CV risk. Albuminuria is thought to reflect generalized transvascular leakiness 7 promoting lipid insudation, atherosclerosis and thrombosis in coronary as well as cerebral arteries and may thereby contribute to development of CV death. High LV mass may promote myocardial ischaemia 31 compromising LV function and increasing the risk of fatal arrythmia. 32 Whether high UACR and LV mass strictly speaking are CV risk factors is uncertain and will require additional longitudinal studies evaluating whether reduction in UACR and/ or LV mass convey improved prognosis.
As albuminuria and LV mass are independent CV risk markers and perhaps risk factors, it is important to measure both when calculating CV risk in hypertension.
Conclusion
In patients with hypertension and electrocardiographic LV hypertrophy, UACR and LV mass predicted CEP as well as CV death independently of each other, but when taking into account traditional CV risk factors, LV mass did only add significantly to UACR in prediction of CV death.
Limitations
UACR was calculated from a single spot urine that has a rather poor reproducibility. However, the fact that UACR at baseline were related to the same metabolic disturbances as demonstrated in other studies suggests that possible misclassification is unlikely to have been a major problem.
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